Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights
Joint Authors
Petrioli, Roberto
D’Angelo, Alberto
Roudi, Raheleh
Mini, Enrico
Roviello, Giandomenico
Source
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-07-04
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
Metastatic gastric cancer is still a disease with a poor prognosis.
Recently, different novel agents (e.g., apatinib, nivolumab, TAS-102) have demonstrated a survival advantage compared with placebo for patients with heavily pretreated metastatic gastric cancer.
Although the possible availability of active agents may be a desirable option in a very poor therapeutic scenario, clinical data from the recent studies with these drugs raise yet controversial issues.
The purpose of this review is to briefly summarize the results of these novel drugs focusing on the limitations that bring some shadows on their positive therapeutic results.
American Psychological Association (APA)
Roviello, Giandomenico& D’Angelo, Alberto& Roudi, Raheleh& Petrioli, Roberto& Mini, Enrico. 2019. Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights. Journal of Oncology،Vol. 2019, no. 2019, pp.1-9.
https://search.emarefa.net/detail/BIM-1184334
Modern Language Association (MLA)
Roviello, Giandomenico…[et al.]. Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights. Journal of Oncology No. 2019 (2019), pp.1-9.
https://search.emarefa.net/detail/BIM-1184334
American Medical Association (AMA)
Roviello, Giandomenico& D’Angelo, Alberto& Roudi, Raheleh& Petrioli, Roberto& Mini, Enrico. Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights. Journal of Oncology. 2019. Vol. 2019, no. 2019, pp.1-9.
https://search.emarefa.net/detail/BIM-1184334
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1184334